ZA982533B - Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid - Google Patents

Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid

Info

Publication number
ZA982533B
ZA982533B ZA982533A ZA982533A ZA982533B ZA 982533 B ZA982533 B ZA 982533B ZA 982533 A ZA982533 A ZA 982533A ZA 982533 A ZA982533 A ZA 982533A ZA 982533 B ZA982533 B ZA 982533B
Authority
ZA
South Africa
Prior art keywords
microparticles
sustained
hyaluronic acid
release composition
drugs encapsulated
Prior art date
Application number
ZA982533A
Other languages
English (en)
Inventor
Myung-Jin Kim
Oh-Ryong KWON
Sun-Jun Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19501732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA982533(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ZA982533B publication Critical patent/ZA982533B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA982533A 1997-04-01 1998-03-25 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid ZA982533B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970012046A KR100236771B1 (ko) 1997-04-01 1997-04-01 히아루론산을 이용한 약물의 서방성 미세입자 제형

Publications (1)

Publication Number Publication Date
ZA982533B true ZA982533B (en) 1998-09-30

Family

ID=19501732

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA982533A ZA982533B (en) 1997-04-01 1998-03-25 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid

Country Status (26)

Country Link
US (3) US20080063727A1 (xx)
EP (1) EP0918535B1 (xx)
JP (1) JP3445283B2 (xx)
KR (1) KR100236771B1 (xx)
CN (1) CN1132625C (xx)
AR (1) AR011208A1 (xx)
AT (1) ATE285245T1 (xx)
AU (1) AU721929B2 (xx)
BG (1) BG64642B1 (xx)
BR (1) BR9804802B1 (xx)
CA (1) CA2256596C (xx)
DE (1) DE69828252T2 (xx)
DK (1) DK0918535T3 (xx)
ES (1) ES2232939T3 (xx)
HK (1) HK1020885A1 (xx)
HU (1) HUP0000737A3 (xx)
ID (1) ID20584A (xx)
IL (1) IL127220A (xx)
MY (1) MY132812A (xx)
NZ (1) NZ333019A (xx)
PL (1) PL195223B1 (xx)
PT (1) PT918535E (xx)
TR (1) TR199802500T1 (xx)
TW (1) TW514532B (xx)
WO (1) WO1998043664A1 (xx)
ZA (1) ZA982533B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221854B1 (en) * 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
AU3055099A (en) 1998-05-20 1999-12-06 Charna Chemicals Ltd. A pharmaceutical formulation for nasal administration
AU4356299A (en) * 1998-06-29 2000-01-17 White Spot Ag Utilization of growth factors for the production of medicaments
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
NZ506975A (en) * 1999-01-18 2004-01-30 Lg Chemical Ltd Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
CA2400172C (en) 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
TW200526253A (en) 2003-11-14 2005-08-16 Chugai Pharmaceutical Co Ltd Cross-linked polysaccharide microparticles and process for producing the same
WO2005116130A1 (en) * 2004-05-27 2005-12-08 Novozymes Biopolymer A/S A fast dissolving dried hyaluronic acid product
US8143391B2 (en) 2004-09-07 2012-03-27 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
TW200640492A (en) * 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
US8017152B2 (en) 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
WO2007028196A1 (en) * 2005-09-07 2007-03-15 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007076131A2 (en) 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
KR100939983B1 (ko) 2006-10-31 2010-02-03 주식회사 엘지생명과학 히아루론산-소수성 폴리 아미노산 공중합체
FR2931360B1 (fr) * 2008-05-20 2012-05-18 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
AU2010239861B2 (en) 2009-04-22 2013-07-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
US9415012B2 (en) * 2011-06-14 2016-08-16 Ipsen Pharma S.A.S. Sustained-release composition containing peptides as active ingredient
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
US9902753B2 (en) 2012-06-05 2018-02-27 Cj Healthcare Corporation Method of purifying a long-acting human growth hormone
WO2015018461A1 (fr) 2013-08-09 2015-02-12 Genbiotech Compositions therapeutiques comprenant d'acide hyaluronique
KR20170054429A (ko) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 치료용 나노입자 및 관련 조성물, 방법, 및 시스템
HUE056849T2 (hu) 2014-11-21 2022-03-28 Ascendis Pharma Endocrinology Div A/S Hosszú hatástartalmú növekedési hormon adagolási formák

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971782A (en) * 1983-09-14 1990-11-20 Peroxydent Group Periodontal composition and method
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
JPH01287041A (ja) * 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
JPH03215430A (ja) * 1990-01-19 1991-09-20 Kita Kiyoshi 関節腔抗凝固剤
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JPH04282322A (ja) * 1991-03-08 1992-10-07 Denki Kagaku Kogyo Kk 生物活性ペプチド製剤
JPH0565231A (ja) * 1991-03-12 1993-03-19 Takeda Chem Ind Ltd エリスロポエチンの持続性製剤
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
JP3449738B2 (ja) * 1991-07-10 2003-09-22 武田薬品工業株式会社 水溶性組成物
JPH05186364A (ja) * 1991-08-01 1993-07-27 Takeda Chem Ind Ltd 水溶性組成物
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
JPH08198772A (ja) * 1994-11-25 1996-08-06 Kirin Brewery Co Ltd 顆粒球コロニー刺激因子含有粉末経鼻投与製剤
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
JPH09309843A (ja) * 1996-05-21 1997-12-02 Shiseido Co Ltd ヒアルロン酸含有経肺投与用製剤
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
NZ506975A (en) * 1999-01-18 2004-01-30 Lg Chemical Ltd Lipophilic microparticles containing a protein drug or antigen and formulation comprising same

Also Published As

Publication number Publication date
BR9804802B1 (pt) 2011-04-19
PT918535E (pt) 2005-03-31
EP0918535A1 (en) 1999-06-02
EP0918535B1 (en) 2004-12-22
HK1020885A1 (en) 2000-05-26
AU6524198A (en) 1998-10-22
NZ333019A (en) 1999-08-30
TW514532B (en) 2002-12-21
HUP0000737A2 (hu) 2000-09-28
DK0918535T3 (da) 2005-04-18
ID20584A (id) 1999-01-21
US20130230598A1 (en) 2013-09-05
DE69828252T2 (de) 2005-11-10
PL330230A1 (en) 1999-05-10
KR100236771B1 (ko) 2000-02-01
BG102969A (en) 1999-09-30
AU721929B2 (en) 2000-07-20
MY132812A (en) 2007-10-31
JP3445283B2 (ja) 2003-09-08
CA2256596C (en) 2005-12-13
IL127220A0 (en) 1999-09-22
KR19980075759A (ko) 1998-11-16
US20110020458A1 (en) 2011-01-27
HUP0000737A3 (en) 2003-05-28
CN1222857A (zh) 1999-07-14
DE69828252D1 (de) 2005-01-27
BR9804802A (pt) 1999-08-17
CN1132625C (zh) 2003-12-31
WO1998043664A1 (en) 1998-10-08
US20080063727A1 (en) 2008-03-13
ATE285245T1 (de) 2005-01-15
JPH11513047A (ja) 1999-11-09
IL127220A (en) 2004-12-15
PL195223B1 (pl) 2007-08-31
BG64642B1 (bg) 2005-10-31
AR011208A1 (es) 2000-08-02
TR199802500T1 (xx) 1999-06-21
ES2232939T3 (es) 2005-06-01
CA2256596A1 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
HUP0000737A3 (en) Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
IL123986A0 (en) Antithombotic agents process for their preparation and pharmaceutical compositions comprising them
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
HUP9601698A3 (en) Pharmaceutical composition of adiabetical activity
GB0117041D0 (en) Pharmaceutical composition having appetite suppressant activity
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
IL114407A0 (en) Novel peptides and pharmaceutical compositions comprising them
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
IL138137A (en) Cholenic acid amides and pharmaceutical compositions thereof
HUP0003189A3 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
HK1028561A1 (en) Pharmaceutical composition for reducing production of mcp-1 protein
AP9801279A0 (en) Encapsulated solution dosage forms of sertraline
GB9310781D0 (en) Preparation of microparticles
IL134050A0 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
GB9720963D0 (en) Pharmaceutical compositions and method of production
HUP0004274A3 (en) Bispyrido-cycloheptane compounds and pharmaceutical compositions thereof
SI0980241T1 (en) Gelatine encapsulated solution dosage forms of sertraline
ZA987961B (en) Substituted carboxamidothiazoles their preparation and pharmaceutical compositions containing them
HU9702369D0 (en) Pharmaceutical composition of natural active components
HUP9902470A3 (en) Biphenylsulfonylamino alkylcarboxylic acid derivatives and pharmaceutical compositions containing them
HUP9903370A3 (en) Beta-sulfonamido hydroxamic acids and pharmaceutical compositions containing them
GB9725044D0 (en) Microparticles and their therapeutic use